Neurotensin receptor antagonist SR 142948A alters Fos expression and extrapyramidal side effect profile of typical and atypical antipsychotic drugs.
Antipsychotic drugs (APDs) have previously been shown to alter Fos expression in a regionally specific manner. Increases in Fos expression in the nucleus accumbens (NAcc) are common to all clinically effective APDs. In contrast, APD-induced Fos expression increases in the caudate-putamen (CPu) and prefrontal cortex (PFC) are associated with the extrapyramidal side effect liability of typical APDs or the effectiveness against negative symptoms of atypical APDs, respectively. Considerable evidence suggests that the neuropeptide neurotensin (NT) mediates some of the effects of APDs. To determine whether NT neurotransmission is also involved in APD-induced Fos expression in brain regions relevant for therapeutic efficacy, the NT receptor antagonist SR 142948A (10 or 100 microg/kg i.p.) was coadministered with APDs (haloperidol (2.0 mg/kg s.c.), olanzapine (5 mg/kg i.p.), or clozapine (20 mg/kg s.c.)). Fos expression was evaluated in the PFC, NAcc shell, dorsomedial, and dorsolateral CPu and the lateral septum. SR 142948A attenuated haloperidol-induced Fos expression in the CPu but, in contrast, increased olanzapine-induced Fos expression in this brain region. The effects of the NT receptor antagonist were paralleled by its effects on catalepsy in olanzapine--but not haloperidol--treated animals.
Laboratory of Neuropsychopharmacology, Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA 30322, USA.
Elisabeth B
EB
Binder
Becky
B
Kinkead
Michael J
MJ
Owens
Charles B
CB
Nemeroff
D000218:Adamantane / Q000031:analogs & derivatives* / Q000494:pharmacology*; D000704:Analysis of Variance; D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D001522:Behavior, Animal; D002375:Catalepsy / Q000139:chemically induced / Q000503:physiopathology; D002452:Cell Count / Q000379:methods; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D007093:Imidazoles / Q000494:pharmacology*; D007150:Immunohistochemistry / Q000379:methods; D008297:Male; D017072:Neostriatum / Q000033:anatomy & histology / Q000187:drug effects* / Q000378:metabolism; D016761:Oncogene Proteins v-fos / Q000378:metabolism*; D017397:Prefrontal Cortex / Q000033:anatomy & histology / Q000187:drug effects*; D051381:Rats; D017207:Rats, Sprague-Dawley; D018028:Receptors, Neurotensin / Q000037:antagonists & inhibitors; D013997:Time Factors
D014150:Antipsychotic Agents; D007093:Imidazoles; D016761:Oncogene Proteins v-fos; D018028:Receptors, Neurotensin; C104418:SR 142948A; D000218:Adamantane